The relationship between ABO blood types and clopidogrel-related low on-treatment platelet reactivity in patients with coronary artery diseases and type 2 diabetes mellitus: a secondary analysis of a prospective cohort study

Abstract Background The risk of bleeding associated with antiplatelet therapy in patients with coronary artery disease (CAD) has received a lot of attention. The aim of this study was to investigate the relationship between ABO blood system and low on-treatment platelet reactivity (LTPR) in patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Menglu Liu, Jiawen Li, Kailun Yan, Kexin Zhang, Pei Zhu, Xiaofang Tang, Deshan Yuan, Yuejin Yang, Runlin Gao, Jinqing Yuan, Xueyan Zhao
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Diabetology & Metabolic Syndrome
Subjects:
Online Access:https://doi.org/10.1186/s13098-025-01716-6
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850273251579658240
author Menglu Liu
Jiawen Li
Kailun Yan
Kexin Zhang
Pei Zhu
Xiaofang Tang
Deshan Yuan
Yuejin Yang
Runlin Gao
Jinqing Yuan
Xueyan Zhao
author_facet Menglu Liu
Jiawen Li
Kailun Yan
Kexin Zhang
Pei Zhu
Xiaofang Tang
Deshan Yuan
Yuejin Yang
Runlin Gao
Jinqing Yuan
Xueyan Zhao
author_sort Menglu Liu
collection DOAJ
description Abstract Background The risk of bleeding associated with antiplatelet therapy in patients with coronary artery disease (CAD) has received a lot of attention. The aim of this study was to investigate the relationship between ABO blood system and low on-treatment platelet reactivity (LTPR) in patients with CAD and type 2 diabetes mellitus (T2DM). Methods This study examined 10,724 consecutive patients who received percutaneous coronary intervention in China between January and December in 2013 and applied logistic regression to assess the association between ABO blood types and LTPR. These patients who were diagnosed with T2DM, had thromboelastogram (TEG) results and were administered clopidogrel were ultimately enrolled. LTPR is defined by a platelet maximum amplitude of < 31 mm on TEG, induced by adenosine diphosphate. Results Among 3,039 patients (mean age, 59.35 ± 9.89; male, 74.60%), 1,089 (35.83%) presented with LTPR. Multivariate logistic regression revealed that blood type O was independently related to higher odds of LTPR (OR O vs. Non−O: 1.298, 95% CI 1.099–1.534) and that blood type A was independently related to lower odds of LTPR (OR A vs. Non−A: 0.804, 95% CI 0.674–0.958). For further analysis, multivariate logistic regression revealed that, compared to blood type A, type O was independently related to higher odds of LTPR (OR O vs. A: 1.409, 95% CI 1.147–1.729). Conclusions This study reported that in patients with CAD and T2DM, blood type O was independently associated with higher odds of LTPR, indicating a greater likelihood of bleeding, while blood type A was independently related to lower odds of LTPR, suggesting a reduced likelihood of bleeding.
format Article
id doaj-art-8a333decad3b4c69a38d748c249000c9
institution OA Journals
issn 1758-5996
language English
publishDate 2025-05-01
publisher BMC
record_format Article
series Diabetology & Metabolic Syndrome
spelling doaj-art-8a333decad3b4c69a38d748c249000c92025-08-20T01:51:32ZengBMCDiabetology & Metabolic Syndrome1758-59962025-05-0117111110.1186/s13098-025-01716-6The relationship between ABO blood types and clopidogrel-related low on-treatment platelet reactivity in patients with coronary artery diseases and type 2 diabetes mellitus: a secondary analysis of a prospective cohort studyMenglu Liu0Jiawen Li1Kailun Yan2Kexin Zhang3Pei Zhu4Xiaofang Tang5Deshan Yuan6Yuejin Yang7Runlin Gao8Jinqing Yuan9Xueyan Zhao10National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeNational Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeNational Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeNational Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeNational Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeNational Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeNational Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeNational Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeNational Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeNational Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeNational Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAbstract Background The risk of bleeding associated with antiplatelet therapy in patients with coronary artery disease (CAD) has received a lot of attention. The aim of this study was to investigate the relationship between ABO blood system and low on-treatment platelet reactivity (LTPR) in patients with CAD and type 2 diabetes mellitus (T2DM). Methods This study examined 10,724 consecutive patients who received percutaneous coronary intervention in China between January and December in 2013 and applied logistic regression to assess the association between ABO blood types and LTPR. These patients who were diagnosed with T2DM, had thromboelastogram (TEG) results and were administered clopidogrel were ultimately enrolled. LTPR is defined by a platelet maximum amplitude of < 31 mm on TEG, induced by adenosine diphosphate. Results Among 3,039 patients (mean age, 59.35 ± 9.89; male, 74.60%), 1,089 (35.83%) presented with LTPR. Multivariate logistic regression revealed that blood type O was independently related to higher odds of LTPR (OR O vs. Non−O: 1.298, 95% CI 1.099–1.534) and that blood type A was independently related to lower odds of LTPR (OR A vs. Non−A: 0.804, 95% CI 0.674–0.958). For further analysis, multivariate logistic regression revealed that, compared to blood type A, type O was independently related to higher odds of LTPR (OR O vs. A: 1.409, 95% CI 1.147–1.729). Conclusions This study reported that in patients with CAD and T2DM, blood type O was independently associated with higher odds of LTPR, indicating a greater likelihood of bleeding, while blood type A was independently related to lower odds of LTPR, suggesting a reduced likelihood of bleeding.https://doi.org/10.1186/s13098-025-01716-6Platelet function testsABO blood-group systemPercutaneous coronary interventionDiabetes mellitusBleeding
spellingShingle Menglu Liu
Jiawen Li
Kailun Yan
Kexin Zhang
Pei Zhu
Xiaofang Tang
Deshan Yuan
Yuejin Yang
Runlin Gao
Jinqing Yuan
Xueyan Zhao
The relationship between ABO blood types and clopidogrel-related low on-treatment platelet reactivity in patients with coronary artery diseases and type 2 diabetes mellitus: a secondary analysis of a prospective cohort study
Diabetology & Metabolic Syndrome
Platelet function tests
ABO blood-group system
Percutaneous coronary intervention
Diabetes mellitus
Bleeding
title The relationship between ABO blood types and clopidogrel-related low on-treatment platelet reactivity in patients with coronary artery diseases and type 2 diabetes mellitus: a secondary analysis of a prospective cohort study
title_full The relationship between ABO blood types and clopidogrel-related low on-treatment platelet reactivity in patients with coronary artery diseases and type 2 diabetes mellitus: a secondary analysis of a prospective cohort study
title_fullStr The relationship between ABO blood types and clopidogrel-related low on-treatment platelet reactivity in patients with coronary artery diseases and type 2 diabetes mellitus: a secondary analysis of a prospective cohort study
title_full_unstemmed The relationship between ABO blood types and clopidogrel-related low on-treatment platelet reactivity in patients with coronary artery diseases and type 2 diabetes mellitus: a secondary analysis of a prospective cohort study
title_short The relationship between ABO blood types and clopidogrel-related low on-treatment platelet reactivity in patients with coronary artery diseases and type 2 diabetes mellitus: a secondary analysis of a prospective cohort study
title_sort relationship between abo blood types and clopidogrel related low on treatment platelet reactivity in patients with coronary artery diseases and type 2 diabetes mellitus a secondary analysis of a prospective cohort study
topic Platelet function tests
ABO blood-group system
Percutaneous coronary intervention
Diabetes mellitus
Bleeding
url https://doi.org/10.1186/s13098-025-01716-6
work_keys_str_mv AT mengluliu therelationshipbetweenabobloodtypesandclopidogrelrelatedlowontreatmentplateletreactivityinpatientswithcoronaryarterydiseasesandtype2diabetesmellitusasecondaryanalysisofaprospectivecohortstudy
AT jiawenli therelationshipbetweenabobloodtypesandclopidogrelrelatedlowontreatmentplateletreactivityinpatientswithcoronaryarterydiseasesandtype2diabetesmellitusasecondaryanalysisofaprospectivecohortstudy
AT kailunyan therelationshipbetweenabobloodtypesandclopidogrelrelatedlowontreatmentplateletreactivityinpatientswithcoronaryarterydiseasesandtype2diabetesmellitusasecondaryanalysisofaprospectivecohortstudy
AT kexinzhang therelationshipbetweenabobloodtypesandclopidogrelrelatedlowontreatmentplateletreactivityinpatientswithcoronaryarterydiseasesandtype2diabetesmellitusasecondaryanalysisofaprospectivecohortstudy
AT peizhu therelationshipbetweenabobloodtypesandclopidogrelrelatedlowontreatmentplateletreactivityinpatientswithcoronaryarterydiseasesandtype2diabetesmellitusasecondaryanalysisofaprospectivecohortstudy
AT xiaofangtang therelationshipbetweenabobloodtypesandclopidogrelrelatedlowontreatmentplateletreactivityinpatientswithcoronaryarterydiseasesandtype2diabetesmellitusasecondaryanalysisofaprospectivecohortstudy
AT deshanyuan therelationshipbetweenabobloodtypesandclopidogrelrelatedlowontreatmentplateletreactivityinpatientswithcoronaryarterydiseasesandtype2diabetesmellitusasecondaryanalysisofaprospectivecohortstudy
AT yuejinyang therelationshipbetweenabobloodtypesandclopidogrelrelatedlowontreatmentplateletreactivityinpatientswithcoronaryarterydiseasesandtype2diabetesmellitusasecondaryanalysisofaprospectivecohortstudy
AT runlingao therelationshipbetweenabobloodtypesandclopidogrelrelatedlowontreatmentplateletreactivityinpatientswithcoronaryarterydiseasesandtype2diabetesmellitusasecondaryanalysisofaprospectivecohortstudy
AT jinqingyuan therelationshipbetweenabobloodtypesandclopidogrelrelatedlowontreatmentplateletreactivityinpatientswithcoronaryarterydiseasesandtype2diabetesmellitusasecondaryanalysisofaprospectivecohortstudy
AT xueyanzhao therelationshipbetweenabobloodtypesandclopidogrelrelatedlowontreatmentplateletreactivityinpatientswithcoronaryarterydiseasesandtype2diabetesmellitusasecondaryanalysisofaprospectivecohortstudy
AT mengluliu relationshipbetweenabobloodtypesandclopidogrelrelatedlowontreatmentplateletreactivityinpatientswithcoronaryarterydiseasesandtype2diabetesmellitusasecondaryanalysisofaprospectivecohortstudy
AT jiawenli relationshipbetweenabobloodtypesandclopidogrelrelatedlowontreatmentplateletreactivityinpatientswithcoronaryarterydiseasesandtype2diabetesmellitusasecondaryanalysisofaprospectivecohortstudy
AT kailunyan relationshipbetweenabobloodtypesandclopidogrelrelatedlowontreatmentplateletreactivityinpatientswithcoronaryarterydiseasesandtype2diabetesmellitusasecondaryanalysisofaprospectivecohortstudy
AT kexinzhang relationshipbetweenabobloodtypesandclopidogrelrelatedlowontreatmentplateletreactivityinpatientswithcoronaryarterydiseasesandtype2diabetesmellitusasecondaryanalysisofaprospectivecohortstudy
AT peizhu relationshipbetweenabobloodtypesandclopidogrelrelatedlowontreatmentplateletreactivityinpatientswithcoronaryarterydiseasesandtype2diabetesmellitusasecondaryanalysisofaprospectivecohortstudy
AT xiaofangtang relationshipbetweenabobloodtypesandclopidogrelrelatedlowontreatmentplateletreactivityinpatientswithcoronaryarterydiseasesandtype2diabetesmellitusasecondaryanalysisofaprospectivecohortstudy
AT deshanyuan relationshipbetweenabobloodtypesandclopidogrelrelatedlowontreatmentplateletreactivityinpatientswithcoronaryarterydiseasesandtype2diabetesmellitusasecondaryanalysisofaprospectivecohortstudy
AT yuejinyang relationshipbetweenabobloodtypesandclopidogrelrelatedlowontreatmentplateletreactivityinpatientswithcoronaryarterydiseasesandtype2diabetesmellitusasecondaryanalysisofaprospectivecohortstudy
AT runlingao relationshipbetweenabobloodtypesandclopidogrelrelatedlowontreatmentplateletreactivityinpatientswithcoronaryarterydiseasesandtype2diabetesmellitusasecondaryanalysisofaprospectivecohortstudy
AT jinqingyuan relationshipbetweenabobloodtypesandclopidogrelrelatedlowontreatmentplateletreactivityinpatientswithcoronaryarterydiseasesandtype2diabetesmellitusasecondaryanalysisofaprospectivecohortstudy
AT xueyanzhao relationshipbetweenabobloodtypesandclopidogrelrelatedlowontreatmentplateletreactivityinpatientswithcoronaryarterydiseasesandtype2diabetesmellitusasecondaryanalysisofaprospectivecohortstudy